Professor Linda Wooldridge

BVSc(Bristol), MSc(Liv.), DPhil(Oxon.)

  • BS8 1TD

  • BS40 5DU

    United Kingdom

20032020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research interests

Summary

The Wooldridge Clinical T cell lab group which is led by Professor Linda Wooldridge has three main areas of interest, these include;

1. CD8+ T cell mediated conditions such as autoimmunity and T cell leukaemia.

 

2. Targeting the CD8 co-receptor for therapeutic benefit.

CD8 has a potent ability to tune the antigen specific immune response. As such, we ae investigating the possiblity that targetting CD8 can be used to:

- Block the pathogenic CD8+ T cell attack observed in autoimmune disease and transplant rejection (Mathew Clement).

- Enhance CD8+ T cell immunity especially in a cancer setting where responses are suboptimal (Tamsin Williams). 

 

Unique Recognition System

CD8+ T cells recognize antigenic determinants in the form of short peptides derived from endogenous peptides bound to MHC class I (pMHCI). CD8+ T cell recognition of pMHCI involves the binding of two receptors (T cell receptor; TCR and CD8) to a single ligand (pMHCI), a modus operandi that is unique to ab T cell biology. Therefore CD8+ T cell activation involves two key interactions:

  1. The TCR/pMHCI interaction: determines antigen specificity. Promiscuity is a characteristic feature of this interaction and it is essential for effective immunity.
  2. The pMHCI/CD8 interaction: has a potent ability to tune the antigen specific immune response by a number of different mechanisms.

 Unique recognition System of the TCR

Figure 1: Interaction between TCR MHCI and CD8

We are interested in understanding both of these interactions and how to manipulate them for therapeutic benefit.

3. Development of technology to study the TCR and CD8 co-receptor. 

 

Our overall aim is to understand the mechanisms of CD8+ T-cell mediated disease and use this knowledge to develop novel therapeutic reagents. 

 

Further information about Professor Linda Wooldridge can be found here.

Fingerprint Dive into the research topics where Linda Wooldridge is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

  • 34 Article (Academic Journal)

GPU-Accelerated Discovery of Pathogen Derived Molecular Mimics of a T-cell Insulin Epitope

Whalley, T., Dolton, G., Brown, P. E., Wall, A., Wooldridge, L., van den Burg, H., Fuller, A., Hopkins, J. R., Crowther, M. D., Attaf, M., Knight, R. R., Cole, D. K., Peakman, M., Sewell, A. K. & Szomolay, B., 28 Feb 2020, In : Frontiers in Immunology. 11, 18 p., 296.

Research output: Contribution to journalArticle (Academic Journal)

Open Access
File
  • 33 Downloads (Pure)

    Divergent roles for antigenic drive in the aetiology of primary versus dasatinib-associated CD8+ TCR-Vβ+ expansions

    Lissina, A., McLaren, J. E., Ilander, M., Andersson, E., Lewis, C. S., Clement, M., Herman, A., Ladell, K., Llewellyn-Lacey, S., Miners, K., Gostick, E., Melenhorst, J. J., Barrett, A. J., Price, D. A., Mustjoki, S. & Wooldridge, L., 7 Feb 2018, In : Scientific Reports. 8, 1, 12 p., 2534.

    Research output: Contribution to journalArticle (Academic Journal)

    Open Access
    File
  • 1 Citation (Scopus)
    238 Downloads (Pure)

    Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs

    Bijen, H. M., van der Steen, D. M., Hagedoorn, R. S., Wouters, A. K., Wooldridge, L., Falkenburg, J. H. F. & Heemskerk, M. H. M., 2 May 2018, In : Molecular Therapy. 26, 5, p. 1206-1214 9 p.

    Research output: Contribution to journalArticle (Academic Journal)

    Open Access
    File
  • 7 Citations (Scopus)
    170 Downloads (Pure)